Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: The diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials

Archives of Ophthalmology

Volumn 127, Issue 12, 2009, Pages 1581-1583

  Bhavsar, Abdhish R ^a   Googe Jr , Joseph M ^b   Stockdale, Cynthia R ^c   Bressler, Neil M ^d   Brucker, Alexander J ^f   Elman, Michael J ^e   Glassman, Adam R ^c  

^a Retina Center of Minnesota   (United States)

^b Southeastern Retina Associates   (United States)

^c JAEB CENTER FOR HEALTH RESEARCH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Elman Retina Group   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; POVIDONE IODINE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; GLUCOCORTICOID; LOCAL ANESTHETIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIUM CULTURE; CLINICAL PROTOCOL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; HUMAN; INCIDENCE; INFECTION RISK; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; BACTERIAL EYE INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISINFECTION; DRUG ANTAGONISM; INJECTION; ISOLATION AND PURIFICATION; LASER COAGULATION; METHODOLOGY; MICROBIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION; RISK FACTOR; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; VITREOUS BODY;

ANESTHETICS, LOCAL; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; DISINFECTION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INJECTIONS; LASER COAGULATION; MACULAR DEGENERATION; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; POVIDONE-IODINE; PROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRIDANS STREPTOCOCCI; VITREOUS BODY;

EID: 73349107165     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.304     Document Type: Article

References (20)

1. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28(10): 1395-1399.
2. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008;28 (4):564-567.
3. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-882.
4. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27(1):10-12.
5. Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application [in German]. Ophthalmologe. 2007;104(11):952-957.
6. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5)(suppl):S3-S19.
7. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769-1775.
8. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño de Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002;109(11):2036-2040.
9. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery, IV: comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103(9):1340-1342.
10. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123(1):39-44.
11. Puustjärvi T, Teräsvirta M, Nurmenniemi P, Lokkila J, Uusitalo H. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol. 2006;244(12): 1633-1637.
12. Sakamoto H, Sakamoto M, Hata Y, Kubota T, Ishibashi T. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol. 2007;17(3):372-376.
13. Yalvac IS, Basci NE, Bozkurt A, Duman S. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg. 2003;29(3):487-491.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27): 2805-2816.
15. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850-857.
16. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
17. Ophthalmology Web site. http://www.asrs.org/home/communicate-and- educate/pat-survey/2008/reports/popup/report.php?question=17. Accessed October 21, 2009.
18. Ophthalmology Web site. http://www.asrs.org/home/communicate-and- educate/pat-survey/2008/reports/popup/report.php?question=18. Accessed October 21, 2009.
19. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144(3):454-456.
20. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmol. 2002;109(5):920-927.